Alkaline phosphatase changes with seladelpar across subgroups of primary biliary cholangitis patients in the response trial
Kris V. Kowdley(Liver Institute Northwest), Charles A. McWherter(University Health Network), Daria B. Crittenden(Gilead Sciences (Canada)), Stephen F. Carroll(IGM Biosciences (United States)), Maurice Stephan Michel(Heidelberg University), Alan Bonder(Beth Israel Deaconess Medical Center), Kidist Yimam(California Pacific Medical Center), Christophe Corpechot(Inserm), K.G. Reddy(University of Chicago), Ke Yang(Northwestern Polytechnical University), Siva Kumar(Cornell University), Edward Mena(California Liver Research Institute)
Cited by 0
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k